Brokerages forecast that NewLink Genetics Corporation (NASDAQ:NLNK) will announce sales of $2.38 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for NewLink Genetics Corporation’s earnings. The highest sales estimate is $5.00 million and the lowest is $300,000.00. NewLink Genetics Corporation posted sales of $15.35 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 84.5%. The firm is expected to report its next earnings report on Tuesday, November 7th.

According to Zacks, analysts expect that NewLink Genetics Corporation will report full year sales of $2.38 million for the current financial year, with estimates ranging from $13.13 million to $23.10 million. For the next financial year, analysts anticipate that the company will report sales of $12.20 million per share, with estimates ranging from $1.10 million to $20.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for NewLink Genetics Corporation.

NewLink Genetics Corporation (NASDAQ:NLNK) last released its quarterly earnings data on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.21. The business had revenue of $10.37 million during the quarter, compared to analyst estimates of $2.65 million. NewLink Genetics Corporation had a negative return on equity of 55.03% and a negative net margin of 161.94%.

Several brokerages have commented on NLNK. ValuEngine cut shares of NewLink Genetics Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday. Stifel Nicolaus upped their target price on shares of NewLink Genetics Corporation from $14.00 to $29.00 and gave the company a “buy” rating in a research report on Monday, September 11th. Cantor Fitzgerald reissued a “buy” rating and issued a $26.00 price target on shares of NewLink Genetics Corporation in a report on Friday, September 8th. Robert W. Baird raised shares of NewLink Genetics Corporation from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $8.00 to $22.00 in a report on Friday, September 8th. Finally, Jefferies Group LLC raised shares of NewLink Genetics Corporation from a “hold” rating to a “buy” rating and boosted their price target for the company from $7.00 to $26.00 in a report on Friday, September 8th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. NewLink Genetics Corporation has a consensus rating of “Buy” and an average target price of $24.17.

WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/17/brokerages-anticipate-newlink-genetics-corporation-nlnk-will-post-quarterly-sales-of-2-38-million.html.

Several hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company grew its holdings in shares of NewLink Genetics Corporation by 3.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock valued at $140,000 after buying an additional 556 shares during the period. State Street Corp boosted its stake in NewLink Genetics Corporation by 1.2% in the 2nd quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock worth $2,875,000 after purchasing an additional 4,630 shares during the period. Tudor Investment Corp ET AL acquired a new position in NewLink Genetics Corporation in the 2nd quarter worth $286,000. PDT Partners LLC boosted its stake in NewLink Genetics Corporation by 160.2% in the 2nd quarter. PDT Partners LLC now owns 115,795 shares of the biotechnology company’s stock worth $851,000 after purchasing an additional 71,295 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in NewLink Genetics Corporation by 40.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 120,767 shares of the biotechnology company’s stock worth $888,000 after purchasing an additional 34,624 shares during the period. 54.78% of the stock is owned by institutional investors.

Shares of NewLink Genetics Corporation (NLNK) opened at 12.67 on Friday. The company’s market capitalization is $372.76 million. The stock’s 50 day moving average price is $8.51 and its 200 day moving average price is $12.83. NewLink Genetics Corporation has a 1-year low of $5.90 and a 1-year high of $25.17.

NewLink Genetics Corporation Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Get a free copy of the Zacks research report on NewLink Genetics Corporation (NLNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.